These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 16983937)

  • 1. In patients treated with peritoneal dialysis, icodextrin improves erythropoietin-resistant anemia through blockade of asialo receptors on hepatocytes.
    Adachi Y; Nakagawa Y; Nishio A
    Adv Perit Dial; 2006; 22():41-4. PubMed ID: 16983937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erythropoietin treatment in peritoneal dialysis patients.
    Nissenson AR
    Perit Dial Int; 1994; 14 Suppl 3():S63-9. PubMed ID: 7948280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: a parallel, randomized, double blind study.
    Pérez-Oliva JF; Casanova-González M; García-García I; Porrero-Martín PJ; Valenzuela-Silva CM; Hernández-Montero T; Lagarde-Ampudia M; Casanova-Kutsareva Y; Avila-Albuerne Y; Vargas-Batista A; Bobillo-López H; Herrera-Valdés R; López-Saura PA;
    BMC Nephrol; 2005 May; 6():5. PubMed ID: 15910687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors related to erythropoietin hypo-responsiveness in patients on chronic peritoneal dialysis.
    Wei M; Bargman JM; Oreopoulos DG
    Int Urol Nephrol; 2007; 39(3):935-40. PubMed ID: 17534732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Controlled study on the improvement of quality of life in elderly hemodialysis patients after correcting end-stage renal disease-related anemia with erythropoietin.
    Moreno F; Aracil FJ; Pérez R; Valderrábano F
    Am J Kidney Dis; 1996 Apr; 27(4):548-56. PubMed ID: 8678066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Erythropoietin-beta in the treatment of anemia in patients with chronic renal insufficiency].
    Dimković N
    Med Pregl; 2001; 54(5-6):235-40. PubMed ID: 11759218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients.
    Beusterien KM; Nissenson AR; Port FK; Kelly M; Steinwald B; Ware JE
    J Am Soc Nephrol; 1996 May; 7(5):763-73. PubMed ID: 8738812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic effects of erythropoietin in patients on peritoneal dialysis.
    Mak RH
    Pediatr Nephrol; 1998 Oct; 12(8):660-5. PubMed ID: 9811391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease.
    Ballal SH; Domoto DT; Polack DC; Marciulonis P; Martin KJ
    Am J Kidney Dis; 1991 Jan; 17(1):29-33. PubMed ID: 1986567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease.
    Ifudu O; Feldman J; Friedman EA
    N Engl J Med; 1996 Feb; 334(7):420-5. PubMed ID: 8552143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of the treatment with human recombinant erythropoietin on anemia in children with end-stage kidney failure. French multicenter study].
    Sinnassamy P; Andre JL; Treize G; Leroy B
    Arch Fr Pediatr; 1993 Mar; 50(3):201-8. PubMed ID: 8338412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of quarterly average achieved hematocrit with mortality in dialysis patients: a time-dependent comorbidity-adjusted model.
    Messana JM; Chuang CC; Turenne M; Wheeler J; Turner J; Sleeman K; Tedeschi P; Hirth R
    Am J Kidney Dis; 2009 Mar; 53(3):503-12. PubMed ID: 19185402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Recombinant human erythropoietin: 18 months of continuous use in substitution hemodialysis].
    Canaud B; Polito-Bouloux C; Rivory JP; Donnadieu P; Taib J; Florence P; Mion C
    Nephrologie; 1990; 11(1):5-10. PubMed ID: 2374643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of recombinant human erythropoietin (EPO) to correct the anemia of end-stage renal disease: a progress report.
    Adamson W; Egrie JC; Browne JK; Downing MR; Eschbach W
    Behring Inst Mitt; 1988 Aug; (83):188-92. PubMed ID: 3071336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant human erythropoietin resistance in hemodialysis. Effects of paired filtration dialysis.
    Carozzi S; Nasini MG; Santoni O; Tirotta A; Sanna A
    ASAIO J; 1997; 43(5):M535-8. PubMed ID: 9360100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter trial of erythropoietin in patients on peritoneal dialysis.
    Nissenson AR; Korbet S; Faber M; Burkart J; Gentile D; Hamburger R; Mattern W; Schreiber M; Swartz R; Van Stone J
    J Am Soc Nephrol; 1995 Jan; 5(7):1517-29. PubMed ID: 7703390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secondary effects of erythropoietin treatment on metabolism and dialysis efficiency in stable hemodialysis patients.
    Buur T; Lundberg M
    Clin Nephrol; 1990 Nov; 34(5):230-5. PubMed ID: 2268981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of adynamic bone disease on responsiveness to recombinant human erythropoietin in peritoneal dialysis patients.
    Kcomt J; Sotelo C; Raja R
    Adv Perit Dial; 2000; 16():294-6. PubMed ID: 11045314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary hyperthyroidism induced erythropoietin-resistant anemia?
    Jyo-Oshiro Y; Nomura S; Fukushima T; Tamai H; Fueki H; Osawa G
    Intern Med; 1997 Dec; 36(12):903-5. PubMed ID: 9475248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythropoietin use in peritoneal dialysis patients.
    Zimmerman SW; Johnson CA
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):38-41. PubMed ID: 1928078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.